Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.08 -6.6%	$0.23	$0.07 ▼ $1.33	$20.54M	2.18	48.68 million shs	26.02 million shs
CING Cingulate	$4.17 -1.0%	$4.62	$1.80 ▼ $20.83	$21.95M	-0.74	140,627 shs	162,051 shs
FBLG FibroBiologics	$0.58 +9.0%	$0.70	$0.53 ▼ $4.41	$24.40M	-0.74	502,197 shs	1.01 million shs
MYNZ Mainz Biomed	$1.43 -1.4%	$1.72	$1.30 ▼ $18.40	$6.55M	0.25	215,911 shs	51,883 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	0.00%	-3.00%	-71.75%	-73.51%	-92.33%
CING Cingulate	0.00%	-18.24%	-5.87%	+3.99%	+1,438.18%
FBLG FibroBiologics	0.00%	-10.21%	-10.26%	-29.88%	-84.39%
MYNZ Mainz Biomed	0.00%	+7.52%	-28.50%	-41.87%	-90.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	2.5566 of 5 stars	4.0	4.0	1.6	0.8	0.0
CING Cingulate	2.8137 of 5 stars	3.5	5.0	1.7	0.8	0.6
FBLG FibroBiologics	3.273 of 5 stars	3.6	4.0	2.5	2.5	0.6
MYNZ Mainz Biomed	2.6275 of 5 stars	3.3	5.0	0.6	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.00	Hold	$1.35	1,644.09% Upside
CING Cingulate	3.00	Buy	$26.00	523.50% Upside
FBLG FibroBiologics	3.20	Buy	$13.00	2,132.14% Upside
MYNZ Mainz Biomed	2.50	Moderate Buy	$14.00	879.02% Upside

Current Analyst Ratings Breakdown

Latest MYNZ, CING, ADAP, and FBLG Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
8/5/2025	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $12.00
8/4/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/29/2025	ADAP Adaptimmune Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/29/2025	ADAP Adaptimmune Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/29/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
7/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/17/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/27/2025	CING Cingulate	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$60.00 ➝ $61.00
5/19/2025	CING Cingulate	Roth Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$12.00 ➝ $11.00

(Data available from 8/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$179.64M	0.11	N/A	N/A	$0.05 per share	1.55
CING Cingulate	N/A	N/A	N/A	N/A	$2.32 per share	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.02 per share	N/A
MYNZ Mainz Biomed	$890K	7.36	N/A	N/A	$2.61 per share	0.55

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	N/A	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
CING Cingulate	-$15.55M	-$8.48	N/A	N/A	N/A	N/A	-229.78%	-142.28%	8/12/2025 (Estimated)
FBLG FibroBiologics	-$11.16M	-$0.36	N/A	N/A	N/A	N/A	-710.25%	-118.02%	N/A
MYNZ Mainz Biomed	-$21.65M	-$65.60	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest MYNZ, CING, ADAP, and FBLG Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CING Cingulate	-$0.82	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.11	N/A	N/A	N/A	$11.04 million	N/A
7/31/2025	Q1 2025	FBLG FibroBiologics	-$0.11	-$0.12	-$0.01	-$0.12	N/A	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/13/2025	Q1 2025	FBLG FibroBiologics	-$0.10	-$0.14	-$0.04	-$0.14	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
CING Cingulate	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
MYNZ Mainz Biomed	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
CING Cingulate	0.16	1.87	1.87
FBLG FibroBiologics	N/A	0.93	0.93
MYNZ Mainz Biomed	0.14	1.32	1.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
CING Cingulate	41.31%
FBLG FibroBiologics	N/A
MYNZ Mainz Biomed	N/A

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
CING Cingulate	5.27%
FBLG FibroBiologics	20.00%
MYNZ Mainz Biomed	18.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
CING Cingulate	20	5.26 million	4.99 million	Not Optionable
FBLG FibroBiologics	10	41.89 million	33.51 million	N/A
MYNZ Mainz Biomed	30	4.58 million	3.75 million	Not Optionable

MYNZ, CING, ADAP, and FBLG Headlines

Recent News About These Companies

Mainz Biomed Announces Pricing of $3.0 Million Follow-On Offering of Ordinary Shares and Warrants

August 4, 2025 | globenewswire.com

Mainz Biomed files to sell 1.47M ordinary units

July 31, 2025 | msn.com

EQS-News: Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

July 24, 2025 | finanzen.atF

Mainz Biomed and CARE Conclude Cooperation Agreement for Joint Care Concept for Health Insurance Companies

July 23, 2025 | globenewswire.com

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

July 15, 2025 | globenewswire.com

Mainz Biomed Half Year 2025 Update: Accelerating FDA Pathway for NextGen Colorectal Cancer Screening and Expansion with Pancreatic Cancer Screening Acquisition

July 15, 2025 | globenewswire.com

Mainz Biomed BV News (MYNZ) - Investing.com

July 4, 2025 | investing.com

Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs

June 25, 2025 | anlegerplus.deA

Mainz BioMed NV: Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

June 25, 2025 | finanznachrichten.de

Mainz Biomed BV Aktie | MYNZ Kurs | Realtime - Investing.com

June 25, 2025 | de.investing.com

EQS-News: Mainz Biomed erhält staatliche Förderung für die Entwicklung seines innovativen Tests zur Früherkennung von Bauchspeicheldrüsenkrebs

June 25, 2025 | boerse.deB

Mainz Biomed Secures Public Funding to Advance Innovative Pancreatic Cancer Screening Test

June 25, 2025 | globenewswire.com

Promising Advancements in Cancer Diagnostics Propel Mainz Biomed B.V. to a Buy Rating

June 11, 2025 | tipranks.com

Mainz BioMed NV: Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

June 10, 2025 | finanznachrichten.de

Mainz Biomed startet Machbarkeitsstudie zu Biomarker-Panel im Rahmen seines Projekts zur Behandlung von Bauchspeicheldrüsenkrebs

June 10, 2025 | anlegerplus.deA

Mainz Biomed Initiates Feasibility Study of Biomarker Panel in Pancreatic Cancer Project

June 10, 2025 | finance.yahoo.com

Mainz Biomed Initiates Feasibility Phase for Non-Invasive Pancreatic Cancer Screening Test in PancAlert Project

June 10, 2025 | quiverquant.comQ

Mainz Biomed N.V. Shareholders Approve Key Proposals at Annual Meeting

June 5, 2025 | tipranks.com

Mainz Biomed N.V. Secures $4 Million Through Securities Offering

May 21, 2025 | tipranks.com

Mainz Biomed prices $4M securities offering

May 20, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Short Squeeze Candidates With Big Catalysts on the Horizon
By Dan Schmidt | July 25, 2025
View 3 Short Squeeze Candidates With Big Catalysts on the Horizon
These 3 Rare Earth Stocks Are Surging Alongside MP Materials
By Leo Miller | July 19, 2025
View These 3 Rare Earth Stocks Are Surging Alongside MP Materials
Why Lucid’s 36% Rally on Uber Deal Could Be a Game-Changer
By Leo Miller | July 22, 2025
View Why Lucid’s 36% Rally on Uber Deal Could Be a Game-Changer
3 Trucking Stocks Getting Big Analyst Upgrades Now
By Gabriel Osorio-Mazilli | August 6, 2025
View 3 Trucking Stocks Getting Big Analyst Upgrades Now
Viasat: Why a Wall of Cash Has Shorts Running for Cover
By Jeffrey Neal Johnson | August 8, 2025
View Viasat: Why a Wall of Cash Has Shorts Running for Cover

MYNZ, CING, ADAP, and FBLG Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.08 -0.01 (-6.63%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.08 +0.00 (+2.97%)

As of 08/8/2025 07:59 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Cingulate NASDAQ:CING

$4.17 -0.04 (-0.95%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$4.28 +0.11 (+2.64%)

As of 08/8/2025 06:55 PM Eastern

Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.

FibroBiologics NASDAQ:FBLG

$0.58 +0.05 (+9.02%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$0.58 -0.01 (-1.10%)

As of 08/8/2025 07:48 PM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

Mainz Biomed NASDAQ:MYNZ

$1.43 -0.02 (-1.38%)

Closing price 08/8/2025 04:00 PM Eastern

Extended Trading

$1.44 +0.01 (+0.70%)

As of 08/8/2025 06:23 PM Eastern

Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time